40
Participants
Start Date
March 22, 2023
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2027
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
The RP2D of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel determined in Part A will be used in Part B dose expansion.
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
New York Presbyterian/Weill-Cornell Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
University of Pennsylvania, Philadelphia
University of Michigan Cancer Center, Ann Arbor
University of Chicago, Chicago
Washington University School of Medicine, St Louis
University of Utah Huntsman Cancer Institute, Salt Lake City
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Virginia Mason Medical Center, Seattle
Fred Hutchinson Cancer Center, Seattle
Dana Farber Cancer Institute, Boston
Verastem, Inc.
INDUSTRY